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Why Is This Necessary?
• As the vaccine becomes approved for emergency use by the FDA, patients 
are bringing questions to their visits
• With an abundance of information online and in the news, it can be difficult 
to boil down to the basics and know that the information you are reading is 
accurate
• Time spent discussing the COVID vaccine takes away from time discussing 
other chronic health conditions
• With information about the vaccine constantly evolving, distributing 
material with accurate information as well as trustworthy sites that are 
continually being updated is crucial
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Cost Considerations
• COVID-19 has had an incredible financial impact 
worldwide
• Widespread distribution of the COVID-19 vaccine is one 
step towards returning to a state of “normal,” which 
would allow many operations and industries to return to 
the level of financial independence they experienced 
prior to the COVID-19 pandemic
• Patient education is critical for distribution of the 
vaccine, especially as it does not have the same level of 
efficacy and safety data or history as other vaccines
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Perspective
• Umair Malik, MD (community 
member and physician at NCPC)
 Healthcare providers are facing 
information distributed on platforms 
that many people trust (Facebook, 
Instagram influencers) with 
information that we cannot assure is 
100% true
 Inherent uncertainty makes it difficult 
to make assertive claims about benefits 
of the vaccine
 Physicians have a duty to debunk false 
information that patients believe, or at 
least present evidence-based 
information
 All of this must be done in a 15 minute 
visit during which other medical 
conditions must be addressed as well
• Robert Wilson (community member 
and board member of North Country 
Hospital)
 It is important to get information out 
on multiple levels, including targeting 
various age groups, education levels, 
and medical conditions; this can be 
done all in one deliverable but must be 
clear and concise
 Key information to include: a basic 
explanation of how the vaccine works, 
who it is safe for, and addressing the 





• In collaboration with Zeynep Tek, MS-
3 a handout was created with many 
frequently asked questions about the 
COVID-19 vaccine identified by 
physicians and nurses
• State-specific information about 
vaccine distribution schedule was 
included on the back of the handout
• Claudia Russell, MS-3 developed 
surveys about patient thoughts on the 
vaccine that were distributed at three 




• 51 Surveys were collected across three 
different sites in South Burlington 
(VT), Newport (VT), and Ridgefield 
(CT)
• Ages of participants:
 18-29: 1 (2%)
 30-49: 11 (21.5%)
 50-64: 18 (35.3%)
 65-79: 16 (31.4%) 
 80+: 5 (9.8%)
• Gender: 23 participants were male 
(45.1%), 28 were female (54.9%)
• Of those surveyed, 40 said they would 
receive the vaccine (78.4%), 2 said 
they would not receive the vaccine 
(3.9%), and 9 were unsure (17.7%)
• When asked about why patients 
would not receive the vaccine, the 
following responses were collected: 
 I don’t want it: 1 
 I worry I will get sick from it: 2
 I worry about long term side effects: 6 
 I need more information: 5 
 I don’t trust the vaccine: 2 
 Other answers: 5 
 Too many allergies: 3
 I don’t trust the vaccine up to 10 years 
coming out
 I think it was rushed to be made 
 I want to wait
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Effectiveness & Limitations
• The effectiveness of this deliverable has not yet been evaluated on a large-
scale
• Proposed methods to evaluate this project:
 Interviewing physicians and nurses before and after distribution of the handout to 
determine if it has decreased the amount of time discussing the COVID-19 vaccine
 Interviewing patients before and after distribution of the handout to determine if 
they feel they are better able to make an informed decision about the vaccine when 
it becomes offered to them
• Limitations of this project:
 Information that continues to change and evolve, creating the possible need to 
update the handout
 Handout has only been developed in English
 Distribution is currently limited to in-office, and making it more widespread could 
involve time and money for administration to reach patients that rely on physical 
mail
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Recommendations for Future 
Interventions
• Distribute handout at more practices across Vermont
• Update handout with most accurate and current information available
• Analyze effectiveness using the methods outlined previously
• Interview patients about the data they are most curious and concerned 
about regarding the COVID-19 vaccine
• Write an editorial for local newspapers regarding information on the vaccine 
to reach a broader population
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